repaglinide 1 MG Oral Tablet

1 INDICATIONS AND USAGE Repaglinide Tablets, USP (repaglinide) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Repaglinide Tablets, USP (repaglinide) should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Repaglinide Tablets is a glinide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1) Limitation of Use: Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis ( 1 )

breckenridge pharmaceutical, inc.

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] nausea` `[3] diarrhoea` `[4] off label use` `[5] vomiting` `[6] fatigue` `[7] dependence` `[8] pyrexia` `[9] death` `[10] neutropenia`

3 years ago

ROUND YELLOW B854

16 HOW SUPPLIED/STORAGE AND HANDLING Repaglinide Tablets, USP (repaglinide) are supplied as round tablets and colored to indicate strength, available in 0.5 mg (white), 1 mg (light yellow) and 2 mg (light red) strengths. Tablets are engraved with "B853" for 0.5 mg, "B854" for 1 mg, and "B855" for 2 mg tablets on the face of the tablet and blank on the back of the tablet. 0.5 mg tablets (white) Bottles of 100 NDC 51991-853-01 1 mg tablets (light yellow) Bottles of 100 NDC 51991-854-01 2 mg tablets (light red) Bottles of 100 NDC 51991-855-01 Store at 20 o to 25 o C (68 o to 77 o F) [see USP Controlled Room Temperature]. Protect from moisture. Keep bottles tightly closed. Dispense in tight containers with child resistant closure.

More pills like ROUND B854

Related Pills

repaglinide 0.5 MG Oral Tablet

breckenridge pharmaceutical, inc.

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site